HAEMONETICS® 1 Exhibit 99.1 Investor Contacts Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 olga.guyette@haemonetics.com | --- | |----------------------------------------------| | | | Media Contact | | Josh Gitelson, Sr. Director-Communications | | (781) 356-9776 josh.gitelson@haemonetics.com | David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports First Quarter Fiscal 2025 Results; Reaffirms Fiscal 2025 Guidance Boston, MA, August ...

Shares of Haemonetics (HAE) have gained 2.4% over the past four weeks to close the last trading session at $86.20, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $112.17 indicates a potential upside of 30.1%. The average comprises six short-term price targets ranging from a low of $94 to a high of $125, with a standard deviation of $10.87. While the lowest estimate indicates an ...

CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has ser ...

"More than 20 years after the first introduction of TAVI in France, the SavvyWire guidewire brings unique capabilities to European markets to help further streamline and optimize the procedure through efficient, predictable wire performance and LV pacing," said Dr. Lionel Leroux from CHU Bordeaux. Professor Thomas Modine of CHU Bordeaux added, "This wire marks an important step in the assessment of TAVI patients. With one wire in the same position, there are less manipulations and we are enabled to continuo ...

BOSTON, July 30, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced CE Mark certification and the first commercial European procedures for the SavvyWire® PreShaped Pressure Guidewire. The SavvyWire guidewire is the world's first and only sensor-guided 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI), designed to improve procedural efficiency with p ...

Haemonetics (HAE) is scheduled to report first-quarter fiscal 2025 results on Aug 8, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of 90 cents surpassed the Zacks Consensus Estimate by 2.27%. The Zacks Consensus Estimate for EPS of $1.03 indicates a year-over-year decline of 1.9%. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Hospital revenues in the fiscal first quarter are once again expected to hav ...

Right now, both Haemonetics and Boston Scientific are sporting a Zacks Rank of # 2 (Buy). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that both of these companies have improving earnings outlooks. But this is just one factor that value investors are interested in. Another notable valuation metric for HAE is its P/B ratio of 4.77. The P/B ratio pits a stock's market value against its book value, which is defined as tota ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. It also includes access to the Zacks Style Scores. Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days. The Style Scores are broken down into four categ ...

Within Plasma, revenues revenues grew 6% in the fourth quarter of fiscal 2024, driven primarily by disposable volume and software. The collections environment in the United States continued to be favorable, with disposables growing 4% in the quarter and 13% in fiscal 2024. Excluding the effects of the Consolidated Screening List's (CSL) U.S. Transitional supply agreement, the company's core plasma business is projected to deliver additional growth of 8% to 12% in fiscal 2025. Other Key Picks MEDP's earnings ...

The higher the broader indexes go, the more conscious investors will be of investments that may offer defensive safety. Because of the essentiality of health-related services this makes medical stocks worth monitoring in this regard. The medical sector currently has 30 stocks that comprise spots on the Zacks Strong Buy list (231 total stocks) and Halozyme Therapeutics (HALO) and Neurocrine Biosciences (NBIX) are two of the new additions this week. HALO and NBIX have risen 40% in the last year and are two of ...